|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang Q, Han L, Li J, Xu H, Liu X, Wang X,
Pan C, Lei C, Chen H and Lan X: Activation of Nrf2 by phloretin
attenuates palmitic acid-induced endothelial cell oxidative stress
via AMPK-dependent signaling. J Agric Food Chem. 67:120–131. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang G, Gao Y, Wang H, Wang J and Niu X:
Phloretin reduces cell injury and inflammation mediated by
staphylococcus aureus via targeting sortase B and the molecular
mechanism. Appl Microbiol Biotechnol. 102:10665–10674. 2018.
View Article : Google Scholar
|
|
4
|
Xu M, Gu W, Shen Z and Wang F: Anticancer
activity of phloretin against human gastric cancer cell lines
involves apoptosis, cell cycle arrest, and inhibition of cell
invasion and JNK signalling pathway. Med Sci Monit. 24:6551–6558.
2018. View Article : Google Scholar
|
|
5
|
Kim U, Kim CY, Lee JM, Oh H, Ryu B, Kim J
and Park JH: Phloretin inhibits the human prostate cancer cells
through the generation of reactive oxygen species. Pathol Oncol
Res. 26:977–984. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hsiao YH, Hsieh MJ, Yang SF, Chen SP, Tsai
WC and Chen PN: Phloretin suppresses metastasis by targeting
protease and inhibits cancer stemness and angiogenesis in human
cervical cancer cells. Phytomedicine. 62:1529642019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin ST, Tu SH, Yang PS, Hsu SP, Lee WH, Ho
CT, Wu CH, Lai YH, Chen MY and Chen LC: Apple polyphenol phloretin
inhibits colorectal cancer cell growth via inhibition of the type 2
glucose transporter and activation of p53-mediated signaling. J
Agric Food Chem. 64:6826–6837. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park SY, Kim EJ, Shin HK, Kwon DY, Kim MS,
Surh YJ and Park JH: Induction of apoptosis in HT-29 colon cancer
cells by phloretin. J Med Food. 10:581–586. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
von Karstedt S, Montinaro A and Walczak H:
Exploring the TRAILs less travelled: TRAIL in cancer biology and
therapy. Nat Rev Cancer. 17:352–366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sedger LM, Glaccum MB, Schuh JC, Kanaly
ST, Williamson E, Kayagaki N, Yun T, Smolak P, Le T, Goodwin R and
Gliniak B: Characterization of the in vivo function of
TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using
TRAIL/Apo2L gene-deficient mice. Eur J Immunol. 32:2246–2254. 2002.
View Article : Google Scholar
|
|
12
|
Cretney E, Takeda K, Yagita H, Glaccum M,
Peschon JJ and Smyth MJ: Increased susceptibility to tumor
initiation and metastasis in TNF-related apoptosis-inducing
ligand-deficient mice. J Immunol. 168:1356–1361. 2002. View Article : Google Scholar
|
|
13
|
Takeda K, Smyth MJ, Cretney E, Hayakawa Y,
Kayagaki N, Yagita H and Okumura K: Critical role for tumor
necrosis factor-related apoptosis-inducing ligand in immune
surveillance against tumor development. J Exp Med. 195:161–169.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gong H, Cheng W and Wang Y: Tumor necrosis
factor-related apoptosis-inducing ligand inhibits the growth and
aggressiveness of colon carcinoma via the exogenous apoptosis
signaling pathway. Exp Ther Med. 17:41–50. 2019.PubMed/NCBI
|
|
15
|
Ivanov VN, Bhoumik A and Ronai Z: Death
receptors and melanoma resistance to apoptosis. Oncogene.
22:3152–3161. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang XD, Franco A, Myers K, Gray C,
Nguyen T and Hersey P: Relation of TNF-related apoptosis-inducing
ligand (TRAIL) receptor and FLICE-inhibitory protein expression to
TRAIL-induced apoptosis of melanoma. Cancer Res. 59:2747–2753.
1999.PubMed/NCBI
|
|
17
|
Abe K, Kurakin A, Mohseni-Maybodi M, Kay B
and Khosravi-Far R: The complexity of TNF-related
apoptosis-inducing ligand. Ann N Y Acad Sci. 926:52–63. 2000.
View Article : Google Scholar
|
|
18
|
Kim JL, Park SH, Jeong S, Kim BR, Na YJ,
Jo MJ, Jeong YA, Yun HK, Kim DY, Kim BG, et al: Sea cucumber
(Stichopus japonicas) F2 enhanced TRAIL-induced apoptosis via XIAP
ubiquitination and ER stress in colorectal cancer cells. Nutrients.
11:10612019. View Article : Google Scholar
|
|
19
|
Kim B, Seo JH, Lee KY and Park B: Icariin
sensitizes human colon cancer cells to TRAIL-induced apoptosis via
ERK-mediated upregulation of death receptors. Int J Oncol.
56:821–834. 2020.
|
|
20
|
Mahalingam D, Carew JS, Espitia CM, Cool
RH, Giles FJ, de Jong S and Nawrocki ST: Heightened JNK activation
and reduced XIAP levels promote TRAIL and sunitinib-mediated
apoptosis in colon cancer models. Cancers (Basel). 11:8952019.
View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi BY: Biochemical basis of
anti-cancer-effects of phloretin-a natural dihydrochalcone.
Molecules. 24:2782019. View Article : Google Scholar
|
|
23
|
Wu C: Systemic therapy for colon cancer.
Surg Oncol Clin N Am. 27:235–242. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Walczak H, Miller RE, Ariail K, Gliniak B,
Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al:
Tumoricidal activity of tumor necrosis factor-related
apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ashkenazi A, Pai RC, Fong S, Leung S,
Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert
A, et al: Safety and antitumor activity of recombinant soluble Apo2
ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar
|
|
26
|
Lemke J, von Karstedt S, Zinngrebe J and
Walczak H: Getting TRAIL back on track for cancer therapy. Cell
Death Differ. 21:1350–1364. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Surapally S, Jayaprakasam M and Verma RS:
Curcumin augments therapeutic efficacy of TRAIL-based immunotoxins
in leukemia. Pharmacol Rep. 72:1032–1046. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cao X, Fang L, Gibbs S, Huang Y, Dai Z,
Wen P, Zheng X, Sadee W and Sun D: Glucose uptake inhibitor
sensitizes cancer cells to daunorubicin and overcomes drug
resistance in hypoxia. Cancer Chemother Pharmacol. 59:495–505.
2007. View Article : Google Scholar
|
